Marina was in her late sixties when her family, rather than Marina herself, first raised the concern. She was repeating questions within the same conversation, losing track of appointments she used to manage without a diary, and twice had misplaced her car in a car park she had used weekly for years. She herself described it as "just tiredness." Her children described it with more concern than that.
This is the presentation that is easiest to under-triage. It does not look like dementia. It looks like a busy, ageing brain having an ordinary bad stretch. The distinction matters enormously, because mild cognitive impairment — the stage before dementia, where daily function is still largely preserved but memory testing shows measurable decline — is the window where intervention has the best chance of changing trajectory. Wait for a dementia-level presentation and that window has, by definition, mostly closed.
We addressed Marina's presentation as a case for structured cognitive testing and a multi-domain root-cause workup from the first visit, rather than reassurance and a wait-and-see review in six months.
Our approach followed the Bredesen framework for cognitive decline, which manages Alzheimer's-spectrum decline not as a single disease process but as the downstream result of multiple contributing factors operating together — chronic inflammation, brain atrophy, cardiovascular compromise, nutrient deficiencies, toxic burden, and hormonal imbalance among them. That framework directly shaped the panel: rather than a single dementia screen, we ran a multi-domain workup designed to identify which of these factors were actually present in Marina, since not every factor is present in every patient.
The point of running all six domains is that the intervention plan depends entirely on which ones come back abnormal. Managing "cognitive decline" as one thing, rather than as the sum of whichever factors are actually driving it in this patient, is the mistake the framework is built to avoid.
Marina's baseline MoCA score placed her in the range consistent with mild cognitive impairment — below the normal cut-off, but well short of the severity seen in dementia. That result alone confirmed what the family had noticed was real and measurable, not a normal ageing variant.
Mild cognitive impairment is not a diagnosis of dementia, and not every patient with MCI progresses to it. It is, however, the stage at which the underlying contributing factors described in multi-domain frameworks like Bredesen's are most amenable to intervention, because structural and functional loss is still limited. The clinical priority in a patient like Marina is identifying which specific factors are active and managing them directly, rather than defaulting to a single pharmacological approach.
The panel identified three overlapping contributors in Marina's case. First, elevated inflammatory markers, consistent with a chronic low-grade inflammatory state. Second, a cardiovascular risk profile that had not previously been flagged as clinically significant but that plausibly contributed to reduced cerebral perfusion. Third, suboptimal nutrient status, particularly on markers relevant to neuronal and myelin health. Structural imaging showed mild atrophy changes consistent with early-stage decline, without findings suggestive of a more advanced neurodegenerative process.
Three identifiable, modifiable contributors, in a patient at a stage where modifying them still had a realistic chance of changing the trajectory.
Consistent with the Bredesen-protocol logic that decline results from multiple simultaneous factors, we built a plan addressing each identified contributor concurrently, alongside a targeted pharmacological component.
None of these five components was expected to work in isolation. The premise of the Bredesen-informed approach is that decline of this kind is rarely attributable to a single factor, and the intervention has to match that multiplicity.
We repeated the MoCA at three and six months, alongside the inflammatory and metabolic markers that had been abnormal at baseline.
| Time point | MoCA score (/30) | Classification | Inflammatory markers |
|---|---|---|---|
| Baseline | 22 | Mild cognitive impairment | Elevated |
| 3 months | 24 | Borderline / improving | Trending down |
| 6 months | 27 | Within normal range | Normalised |
A MoCA score of 26 or above is generally addressed as the normal-range cut-off. Marina's move from 22 to 27 over six months represents a return to that range — a meaningfully different trajectory from the progressive decline that brought her family in. Her subjective reports tracked with the numbers: fewer repeated questions, a return to managing her own diary, no further incidents of losing her car.
"My daughter noticed before I did — that's the part that frightened me most. Six months later, I feel like myself again, not because I remember everything, but because I trust my memory again." — Marina, patient
A six-month improvement in MoCA score is a meaningful clinical signal in a patient at the MCI stage. It is not proof that the underlying neurodegenerative risk has been eliminated, and we were explicit with Marina and her family about that distinction.
A favourable trajectory in a case like this does not mean the workup was optimal from day one.
Both changes would have strengthened our confidence in attributing the improvement to the intervention rather than to test–retest variability alone — a limitation worth naming rather than glossing over.
This is not a claim that mild cognitive impairment reliably reverses, or that Cerebrolysin and a Bredesen-informed plan will produce a comparable MoCA improvement in every patient. Cognitive trajectories in this population are heterogeneous, and MCI does not progress to dementia in every patient regardless of intervention — some cases are stable at baseline. Marina's case is one instance of a favourable trajectory, not a demonstrated cure or a guaranteed outcome.
What the case does illustrate is the value of managing cognitive decline as multifactorial from the outset — testing across inflammatory, cardiovascular, nutrient, toxic, and hormonal domains rather than defaulting to a single test or a single mechanism — and of intervening at the MCI stage, while the window for meaningful change is still open.
The forgetting that got noticed was the easy part. The multi-domain workup was what made the difference.
Every clinical relationship at Clinic82 begins with a private consultation with a member of our team — not a sales conversation. If a case here mirrors something you are living with, we would rather you talk to us.
Request a consultation